• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Callisto Pharmaceuticals' CEO to Discuss Company's Anti-Cancer Drug Candidates on Tradersnation.Com Broadcast Tomorrow; CEO Dr. Gary Jacob to Discuss Company's Development Pipeline of New Treatments for Cancer, Other Diseases

Posted on: Monday, 10 October 2005, 03:00 CDT

Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of novel drug therapies in the fight against hematologic cancers and related diseases, has announced that CEO Dr. Gary S. Jacob will be featured on tomorrow's broadcast of Traders Nation(TM), a leading syndicated investment oriented radio talk show. The live interview will also be available simulcast online via the Internet.

Dr. Jacob is expected to provide a brief corporate overview, including details about Callisto's development pipeline of innovative drug treatments for relapsed or refractory acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and other forms of cancer. The interview will include insights about the large U.S. and global demand for innovative new anti-cancer treatments; the clinical studies currently underway of Callisto's lead anti-cancer drug candidates, Atiprimod and Annamycin; and other key topics of interest to biotechnology and/or smallcap stocks investors.

To listen to the live radio interview, please visit www.tradersnation.com/radio.shtml. To view the simulcast televised Web feed, please visit: www.streetcast.tv. To call into the radio show, please use caller line: 1-866-SMCAPPS / 1-866-762-2777.

About Traders Nation(TM)

Traders Nation broadcasts are fed on the New York ABC's Starguide Satellite System which can be received by over 4,000 radio stations across the United States. Station affiliates capture Traders Nation for either a simulcast or rebroadcast of the show. Traders Nation is currently syndicated online with 119 sites carrying the show and is broadcast on WTAN 1400AM & WZHR 1340AM in Tampa, Florida and KWAI 1080AM in Hawaii. Traders Nation is heard by tens of thousands of end users via QuoteStream online financial software. Multiple segments make up the 'live' hour-long Traders Nation program where listeners can gather daily to hear the latest small cap news of the day and scheduled guests, from industry experts and CEOs. Traders also share investing, trading strategies and potential hot stock plays swirl throughout the call-in portion of the show.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company committed to developing innovative anti-cancer drugs to treat blood cancers and related diseases, including acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), relapsed or refractory multiple myeloma, and osteolytic disease. Callisto also has drugs in preclinical development for gastrointestinal inflammation, as well as for protection against the potential bio-warfare agents, staphylococcus and streptococcus. Callisto's two lead anti-cancer products include Annamycin, a novel liposomal drug from the anthracycline family with potentially reduced cardiotoxicity, a patented liposomal formulation, and the potential to circumvent multi-drug resistance in both ALL and AML; and Atiprimod, a small-molecule oral drug with a potential multiplicity of effects, including tumor cell anti-proliferative and anti-angiogenic activities to treat relapsed multiple myeloma (MM). Atiprimod is presently in a Phase I/IIa clinical trial in relapsed or refractory MM patients at four clinical sites in the U.S. In addition to cancer treatments, Callisto is developing a drug pre-clinically for treatment of inflammatory bowel disease (IBD). Callisto also has received a major biodefense partnership grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a monoclonal antibody and vaccine against bacterial superantigen toxins. Bacterial superantigens are among the most lethal of toxins that can potentially be used as bioweapons. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect,""should,""anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.

Source: Business Wire

More News in this Category